XT-150 (Preclinical)
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Xalud Therapeutics
Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.
View full company profileAbout Xalud Therapeutics
Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.
View full company profileAbout Xalud Therapeutics
Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.
View full company profileAbout Xalud Therapeutics
Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |
| NP001 | Neuvivo | Phase 3 |